Key Takeaways:
- Bayer shares surged 20% in Frankfurt after Supreme Court ruling
- The 7-2 decision shields Bayer from Roundup cancer-warning claims
- The ruling caps a decade of litigation costing Bayer over $10 billion
Back
Bayer surges 20% after Supreme Court shields it from Roundup suits
Bayer AG shares surged 20% in Frankfurt trading Thursday after the US Supreme Court shielded the company from tens of thousands of claims that its Roundup herbicide should carry a cancer warning, removing the single biggest legal overhang for the German drugmaker.
The 7-2 ruling threw out a $1.25 million jury verdict won by a Missouri man who blamed Roundup for his non-Hodgkin lymphoma. The majority said consumers can't sue Bayer for the absence of a cancer warning given that federal regulators concluded a cautionary statement wasn't necessary. The decision effectively establishes that federal pesticide labeling requirements preempt state-level failure-to-warn claims.
The ruling will help end a decade-long flood of lawsuits that have cost the company more than $10 billion in settlements and legal fees. Shares jumped as much as 20% when trading resumed on the Frankfurt Stock Exchange, adding billions to Bayer's market capitalization. The company had previously proposed a $7.25 billion settlement to resolve remaining claims, and its stock had fallen 7% on that news in a prior session.
The decision marks a turning point for Bayer, which inherited the Roundup litigation through its $63 billion acquisition of Monsanto in 2018. The company has faced more than 100,000 claims from plaintiffs alleging that Roundup caused non-Hodgkin lymphoma, with juries in earlier trials awarding multi-million-dollar verdicts that were later reduced on appeal. The Supreme Court's ruling now prevents future lawsuits based on state warning requirements, capping Bayer's remaining exposure.
Bayer shares had been under pressure for years due to the litigation overhang, trading well below their pre-acquisition levels. The 20% surge Thursday recovers a significant portion of those losses. Investors will watch for Bayer's next quarterly earnings report for updated litigation reserve disclosures and any changes to the company's financial outlook, including potential dividend policy adjustments.
This article is for informational purposes only and does not constitute investment advice.
[1] 拜耳恢复交易，法兰克福股价涨幅扩大至20%[2] Supreme Court Shields Bayer From Roundup Cancer-Warning Suits[3] Bayer falls 7% after proposing $7.25 billion settlement in Roundup case; European markets end higher[4] Merck KGaA Secures $11.3 Billion Purchase of Bio-Techne[5] Germany's Merck boosts life sciences business with $11 billion Bio-Techne deal
